CHARACTERISTICS OF OLOKIZUMAB PHARMACOKINETICS IN PATIENTS WITH NOVEL CORONAVIRUS INFECTION COVID-19
Authors:
- E. V. TavluevaETE. V. Tavlueva
- E. V. ZernovaEZE. V. Zernova
- M. P. KutepovaMKM. P. Kutepova
- N. E. KostinaNKN. E. Kostina
- V. S. LesinaVLV. S. Lesina
- D. R. MouldDMD. R. Mould
- K. ItoKIK. Ito
- A. V. ZinchenkoAZA. V. Zinchenko
- A. N. DolgorukovaADA. N. Dolgorukova
- M. V. NikolskayaMNM. V. Nikolskaya
- M. S. LemakMLM. S. Lemak
- O. V. FilonOFO. V. Filon
Open Access
- 15 December 2022
- journal article
- research article
- Published by Volgograd State Medical University in Pharmacy & Pharmacology
- Vol. 10 (5) , 460-471-471
Abstract
The aim of the article is to study pharmacokinetic characteristics of intravenous olokizumab in patients with moderate COVID-19 to relieve a hyperinflammation syndrome.Materials and methods. The pharmacokinetic study was conducted as a part of a phase III clinical study (RESET, NCT05187793) on the efficacy and safety of a new olokizumab regimen (intravenous, at the doses of 128 mg or 256 mg) in COVID-19 patients. Plasma concentrations of olokizumab were determined by the enzyme immunoassay. The population analysis was performed using a previously developed pharmacokinetic model based on a linear two compartment.Results. The pharmacokinetic analysis included the data from 8 moderate COVID-19 patients who had been administrated with olokizumab intravenously at the dose of 128 mg. According to the analysis results in this population, there was an increase in the drug clearance, compared with the data obtained in healthy volunteers and the patients with rheumatoid arthritis: 0.435, 0.178 and 0.147 l/day, respectively. The parameters analysis within the framework of a population pharmacokinetic model showed that the main factors for the increased olokizumab clearance are a high body mass index. In addition, the presence of COVID-19 itself is an independent factor in increasing the drug clearance.Conclusion. After the intravenous olokizumab administration, an increase in the drug clearance is observed in moderate COVID-19 patients against the background of the disease course. The main contribution to the increased clearance is made by the characteristics of the population of COVID-19 patients associated with the risk of a severe disease and inflammation. When administered intravenously at the dose of 128 mg, a therapeutically significant olokizumab level was maintained throughout the acute disease phase for 28 days.Keywords
This publication has 25 references indexed in Scilit:
- A pneumonia outbreak associated with a new coronavirus of probable bat originNature, 2020
- Pharmacokinetics of Monoclonal AntibodiesCPT: Pharmacometrics & Systems Pharmacology, 2017
- Profile of sarilumab and its potential in the treatment of rheumatoid arthritisDrug Design, Development and Therapy, 2017
- Efficacy and safety of olokizumab in patients with rheumatoid arthritis with an inadequate response to TNF inhibitor therapy: outcomes of a randomised Phase IIb studyAnnals of the Rheumatic Diseases, 2014
- Safety and pharmacokinetics of olokizumab, an anti‐IL‐6 monoclonal antibody, administered to healthy male volunteers: A randomized phase I studyClinical Pharmacology in Drug Development, 2014
- Discovery and characterization of olokizumabmAbs, 2014
- Tocilizumab: The first interleukin-6-receptor inhibitorAmerican Journal of Health-System Pharmacy, 2008
- Extensions to the Visual Predictive Check to facilitate model performance evaluationJournal of Pharmacokinetics and Pharmacodynamics, 2008
- Diagnosing Model DiagnosticsClinical Pharmacology & Therapeutics, 2007
- Some suggestions for measuring predictive performanceJournal of Pharmacokinetics and Biopharmaceutics, 1981